Skye Bioscience closed at $1.14 on Nov 4, down 6.56%, within 0.0% of its 52-week closing low. Volume of 40.2K shares was 1.63× its 20-day average (above normal).
Split-adjusted performance: -29.6% over one month, -83.3% over six months, -90.5% over one year.
Short interest was 140.3K shares at the Oct 15 settlement, down 5.2% from the prior report (0.6% of float, 4.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SKYESkye Bioscience | $1.14 | −6.56% | −83.3% | — | — | — | $5.0M | |
| IMNNImunon | $0.9070 | +0.78% | −66.5% | — | — | — | $5.1M | Compare |
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | Compare |
| PCSAProcessa Pharmaceuticals | $1.94 | −0.26% | −29.6% | — | — | — | $5.4M | Compare |
| XBIOXenetic Biosciences | $2.01 | −3.37% | −36.6% | +12.0% | −140.7% | — | $4.7M | Compare |
| PULMPulmatrix | $1.52 | +14.29% | +11.8% | — | — | — | $5.6M | Compare |
| TCRTAlaunos Therapeutics | $1.80 | −3.23% | −31.6% | — | — | — | $4.6M | Compare |
| SCNXScienture Holdings | $3.42 | −0.87% | −65.0% | — | −821.3% | — | $5.6M | Compare |
| ACXPAcurx Pharmaceuticals | $1.03 | +0.98% | −50.7% | — | — | — | $5.6M | Compare |
No recent articles focused on Skye Bioscience.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
